Centro Nacional de Investigaciones Oncológicas Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2020
NCT04494958
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Centro Nacional de Investigaciones Oncológicas

Active Ingredients

Drugs in Phase 2 Trials (2)

binimetinib (mektovi) (1 trial)

palbociclib (ibrance) (2 trials)

Drugs in Phase 1 Trials (2)

fulvestrant (faslodex) (1 trial)

rogaratinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4